record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundobservational · manual state transition
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
observational
evidence spans
Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.
US9447085B2 — Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (assignee: Merck Sharp and Dohme LLC) — Represents Merck's commercial IP position on the BACE1 inhibitor scaffold that dominated AD drug development 2012–2018; Phase 3 failure of verubecestat established that BACE inhibition at symptomatic stage is insufficient, reorienting the field toward earlier intervention and combination strategies. · curator_source · 10.1021/acs.jmedchem.6b00307
conditions
Provenance
source title
US9447085B2 — Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (assignee: Merck Sharp and Dohme LLC) — Represents Merck's commercial IP position on the BACE1 inhibitor scaffold that dominated AD drug development 2012–2018; Phase 3 failure of verubecestat established that BACE inhibition at symptomatic stage is insufficient, reorienting the field toward earlier intervention and combination strategies.
doi
10.1021/acs.jmedchem.6b00307
authors
reviewer:will-blair-bot
Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.
vs_5588c5efb07284af · source:US9447085B2 — Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (assignee: Merck Sharp and Dohme LLC) — Represents Merck's commercial IP position on the BACE1 inhibitor scaffold that dominated AD drug development 2012–2018; Phase 3 failure of verubecestat established that BACE inhibition at symptomatic stage is insufficient, reorienting the field toward earlier intervention and combination strategies.|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_945fd8fbbaac1b39finding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
vev_df20b2cdc051c871finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_6f700e042277aa81finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_7029395b74841f83finding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.